Year All2024202320222021202020192018201720162015201420122011 Feb 2, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Dec 29, 2022 FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) Dec 23, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Dec 16, 2022 Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 22, 2022 Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference Nov 16, 2022 Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 16, 2022 Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 4, 2022 National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels Nov 3, 2022 Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights Nov 3, 2022 Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial